Phase III Pivotal comparative clinical trial of intranasal (iNCOVACC) and intramuscular COVID 19 vaccine (Covaxin(®))

One of the most preferable characteristics for a COVID-19 vaccine candidate is the ability to reduce transmission and infection of SARS-CoV-2, in addition to disease prevention. Unlike intramuscular vaccines, intranasal COVID-19 vaccines may offer this by generating mucosal immunity. In this open-la...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Chandramani, Verma, Savita, Reddy, Prabhakar, Diamond, Michael S., Curiel, David T., Patel, Chintan, Jain, Manish Kumar, Redkar, Sagar Vivek, Bhate, Amit Suresh, Gundappa, Vivek, Konatham, Rambabu, Toppo, Leelabati, Joshi, Aniket Chandrakant, Kushwaha, Jitendra Singh, Singh, Ajit Pratap, Bawankule, Shilpa, Ella, Raches, Prasad, Sai, Ganneru, Brunda, Chiteti, Siddharth Reddy, Kataram, Sreenivas, Vadrevu, Krishna Mohan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439197/
https://www.ncbi.nlm.nih.gov/pubmed/37596281
http://dx.doi.org/10.1038/s41541-023-00717-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10439197/
https://www.ncbi.nlm.nih.gov/pubmed/37596281
http://dx.doi.org/10.1038/s41541-023-00717-8

Ejemplares similares